ConductScience.org, home

Paper34799993

Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors.

Wang SY and 10 others. Thorac Cancer, 2022. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors. Papers, record 34799993. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34799993

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors.
PubMed
Journal
Thorac Cancer
PubMed
Year
2022
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.33
iCite
Revised in PubMed
2024-04-05
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wang SYSheng-Yuan
2Lai CHChing-Han
3Chen CWChian-Wei
4Yang SCSzu-Chun
5Chang CCChao-Chun
6Lin CYChia-Ying
7Yen YTYi-Ting
8Tseng YLYau-Lin
9Su PLPo-Lanhttps://orcid.org/0000-0002-8470-6590
10Lin CCChien-Chunghttps://orcid.org/0000-0002-4739-5631
11Su WCWu-Chouhttps://orcid.org/0000-0003-2953-4105

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Adenocarcinoma of LungMajor topic
Lung NeoplasmsMajor topic
Protein Kinase InhibitorsMajor topic
Aged
Chemoradiotherapy
ErbB Receptors
Female
Humans
Male
Middle Aged
Mutation
Progression-Free Survival
Retrospective Studies

Source PubMed

Download CSV of topics

References32

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118378568Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.J Clin Oncol2008https://conductscience.org/library/papers/18378568PubMed
228881918Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol2017https://conductscience.org/library/papers/28881918PubMed
330926356Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non-small-cell Lung Cancer.Clin Lung Cancer2019https://conductscience.org/library/papers/30926356PubMed
433539970Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC.J Thorac Oncol2021https://conductscience.org/library/papers/33539970PubMed
529151359Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.N Engl J Med2018https://conductscience.org/library/papers/29151359PubMed
630152040Comparative effectiveness of concurrent chemoradiotherapy versus EGFR-tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR.Thorac Cancer2018https://conductscience.org/library/papers/30152040PubMed
730059262CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).J Clin Oncol2018https://conductscience.org/library/papers/30059262PubMed
823945383Lung cancer and prognosis in taiwan: a population-based cancer registry.J Thorac Oncol2013https://conductscience.org/library/papers/23945383PubMed
925051378Verification of wild-type EGFR status in non-small cell lung carcinomas using a mutant-enriched PCR on selected cases.J Mol Diagn2014https://conductscience.org/library/papers/25051378PubMed
1028885561Acute and Late Toxicities of Concurrent Chemoradiotherapy for Locally-Advanced Non-Small Cell Lung Cancer.Cancers (Basel)2017https://conductscience.org/library/papers/28885561PubMed
1129864379Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.J Clin Oncol2018https://conductscience.org/library/papers/29864379PubMed
1228885881Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.N Engl J Med2017https://conductscience.org/library/papers/28885881PubMed
1328693247Evaluation of concurrent chemoradiotherapy for locally advanced NSCLC according to EGFR mutation status.Oncol Lett2017https://conductscience.org/library/papers/28693247PubMed
1436119641Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study.Ther Adv Med Oncol2022https://conductscience.org/library/papers/36119641PubMed
1530150014Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.Lancet Respir Med2018https://conductscience.org/library/papers/30150014PubMed
1630153097CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.J Clin Oncol2018https://conductscience.org/library/papers/30153097PubMed
1723211219The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who recieved concurrent chemoradiotherapy.Am J Clin Oncol2014https://conductscience.org/library/papers/23211219PubMed
1831751012Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.N Engl J Med2020https://conductscience.org/library/papers/31751012PubMed
1921904576Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables.Ther Adv Med Oncol2011https://conductscience.org/library/papers/21904576PubMed
2026324372Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.J Clin Oncol2015https://conductscience.org/library/papers/26324372PubMed

See all 32 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
42434745Optimal treatment strategies for unresectable stage III EGFR-mutated non-small cell lung cancer: a systematic review and Bayesian network meta-analysis.Front Oncol2026https://conductscience.org/library/papers/42434745PubMed
41659261Prognostic factors of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor (TKI): a nationwide registry study in China.Transl Lung Cancer Res2026https://conductscience.org/library/papers/41659261PubMed
35806042State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan.Int J Mol Sci2022https://conductscience.org/library/papers/35806042PubMed
34799993Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors.Thorac Cancer2022https://conductscience.org/library/papers/34799993PubMed

Download CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
TXK7294PubTator's text mininghttps://conductscience.org/library/genes/7294NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34799993

GET https://conductscience.org/api/papers/v1/34799993/references?page=2